Cat. No.: ROTC-2603-CXX-002
Description: Tumor immunotherapy has been a major focus of cancer research in recent years. While numerous agents targeting the tumor immune microenvironment, particularly immune checkpoint blockers, are in development, the field still lacks highly predictive models for preclinical evaluation. Current in vitro approaches often rely on tumor cell lines and commercial immune cells, which have limited relevance. To address this gap, a tumor immune microenvironment model has been developed that uses patient-matched tumor organoids and PBMCs.
Price: Inquiry
Datasheet: Datasheet